文献速递泌尿男性生殖肿瘤

单次大剂量放疗对比极限低分割SBRT治疗中危前列腺癌的PROSINT 2期随机试验

Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

PROSINT单中心2期随机试验纳入30例中危前列腺癌患者,1:1随机接受5×9 Gy SBRT或24 Gy单次放疗(SDRT),主要终点为毒性。两组急性和晚期毒性出现时间与持续时间相似,晚期≥2级泌尿毒性HR 1.07(90%CI 0.21-5.57),无≥2级晚期胃肠道毒性;SDRT组20%出现一过性晚期泌尿 flare。SDRT安全、毒性低,肿瘤控制和生活质量终点与SBRT组接近。

要点

  • SDRT 24 Gy单次治疗中危前列腺癌,急性和晚期毒性谱与5×9 Gy SBRT相似。
  • SDRT组20%在9-18个月出现一过性IPSS定义的晚期泌尿flare症状。
  • 两组PSA均降至<0.5 ng/mL,不利中危4年PSA无复发生存SBRT 75.0% vs SDRT 64.0%。

核心结论

  • 在中危前列腺癌患者中,SDRT安全且毒性低,肿瘤控制和生活质量终点与SBRT组高度接近。
  • 鼓励进一步研究探索SDRT用于前列腺癌根治的适应证。

研究设计与样本

  • PROSINT为单中心2期随机临床试验,2015年9月至2017年1月入组30例中危前列腺癌患者。
  • 患者1:1随机接受5×9 Gy SBRT(对照臂)或24 Gy SDRT(试验臂),不允许使用雄激素剥夺治疗。
  • 主要终点为毒性,次要终点包括PSA反应、PSA无复发生存及IPSS和EPIC-26生活质量。

主要发现

  • 两组急性和晚期毒性出现时间及持续时间相似。
  • 晚期 actuarial 泌尿毒性1级HR 0.41(90%CI 0.13-1.27),≥2级HR 1.07(90%CI 0.21-5.57)。
  • 晚期胃肠道毒性1级HR 0.37(90%CI 0.07-1.94),无≥2级晚期胃肠道毒性。
  • 两组36个月时PSA均降至<0.5 ng/mL;有利中危无PSA复发,不利中危4年PSA无复发生存SBRT 75.0% vs SDRT 64.0%(HR 0.76;90%CI 0.17-3.31)。
  • EPIC-26泌尿和胃肠道领域中位评分在1个月短暂下降,3个月恢复至治疗前;SDRT组20%(90%CI 3%-37%)在9-18个月出现IPSS推导的一过性晚期泌尿flare症状。

临床怎么用

  • SDRT 24 Gy单次可作为中危前列腺癌极限低分割SBRT的潜在替代方案,需关注9-18个月一过性泌尿flare。
  • 治疗选择时应结合不利中危因素评估PSA无复发生存差异,并与患者充分沟通。

局限性

  • 单中心2期试验样本量小(30例),结果需更大规模研究验证。
  • 随访和分析时间有限,长期肿瘤控制及晚期毒性仍需延长观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ultra-high single-dose radiotherapy (SDRT) represents a potential alternative to curative extreme hypofractionated stereotactic body radiotherapy (SBRT) in organ-confined prostate cancer. OBJECTIVE: To compare toxic effect profiles, prostate-specific antigen (PSA) responses, and quality-of-life end points of SDRT vs extreme hypofractionated SBRT. DESIGN, SETTING, AND PARTICIPANTS: The PROSINT single-institution phase 2 randomized clinical trial accrued, between September 2015 and January 2017, 30 participants with intermediate-risk prostate cancer to receive SDRT or extreme hypofractionated SBRT. Androgen deprivation therapy was not permitted. Data were analyzed from March to May 2020. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive 5 × 9 Gy SBRT (control arm) or 24 Gy SDRT (test arm). MAIN OUTCOMES AND MEASURES: The primary end point was toxic effects; the secondary end points were PSA response, PSA relapse-free survival, and patient-reported quality of life measured with the International Prostate Symptom Score (IPSS) and Expanded Prostate Cancer Index Composite (EPIC)-26 questionnaires. RESULTS: A total of 30 men were randomized; median (interquartile range) age was 66.3 (61.2-69.9) and 73.6 (64.7-75.9) years for the SBRT and SDRT arms, respectively. Time to appearance and duration of acute and late toxic effects were similar in the 2 trial arms. Cumulative late actuarial urinary toxic effects did not differ for grade 1 (hazard ratio [HR], 0.41; 90% CI, 0.13-1.27) and grade 2 or greater (HR, 1.07; 90% CI, 0.21-5.57). Actuarial grade 1 late gastrointestinal (GI) toxic effects were comparable (HR, 0.37; 90% CI, 0.07-1.94) and there were no grade 2 or greater late GI toxic effects. Declines in PSA level to less than 0.5 ng/mL occurred by 36 months in both study arms. No PSA relapses occurred in favorable intermediate-risk disease, while in the unfavorable category, the actuarial 4-year PSA relapse-free survival values were 75.0% vs 64.0% (HR, 0.76; 90% CI, 0.17-3.31) for SBRT vs SDRT, respectively. The EPIC-26 median summary scores for the genitourinary and GI domains dropped transiently at 1 month and returned to pretreatment scores by 3 months in both arms. The IPSS-derived transient late urinary flare symptoms occurred at 9 to 18 months in 20% (90% CI, 3%-37%) of patients receiving SDRT. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial among patients with intermediate-risk prostate cancer, SDRT was safe and associated with low toxicity, and the tumor control and quality-of-life end points closely match the SBRT arm outcomes. Further studies are encouraged to explore indications for SDRT in the cure of prostate cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02570919.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Greco C, Pares O, Pimentel N, et al. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33704378. doi:10.1001/jamaoncol.2021.0039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。